Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: A prospective, parallel, open-label, two-year extension study

Stefano Palomba, Francesco Manguso, Francesco Orio, Tiziana Russo, Rosamaria Oppedisano, Angela Sacchinelli, Angela Falbo, Achille Tolino, Fulvio Zullo, Pasquale Mastrantonio

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate long-term efficacy of risedronate in osteoporotic postmenopausal patients with inflammatory bowel disease (IBD). Design: A prospective, parallel, open-label, 2-year extension study of a randomized, double-blind, 1-year clinical trial. Eighty-one osteoporotic postmenopausal women with IBD were treated with risedronate (n = 40) or placebo (n = 41). Bone mineral density (BMD), biochemical bone turnover markers, and vertebral and nonvertebral fractures were assessed throughout the study. Data were analyzed using the intent-to-treat principle. Results: Significant (P

Original languageEnglish
Pages (from-to)730-736
Number of pages7
JournalMenopause
Volume15
Issue number4
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Inflammatory Bowel Diseases
Bone Remodeling
Bone Density
Placebos
Clinical Trials
Risedronate Sodium

Keywords

  • Bone fractures
  • Inflammatory bowel disease
  • Osteoporosis
  • Postmenopause
  • Risedronate

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease : A prospective, parallel, open-label, two-year extension study. / Palomba, Stefano; Manguso, Francesco; Orio, Francesco; Russo, Tiziana; Oppedisano, Rosamaria; Sacchinelli, Angela; Falbo, Angela; Tolino, Achille; Zullo, Fulvio; Mastrantonio, Pasquale.

In: Menopause, Vol. 15, No. 4, 07.2008, p. 730-736.

Research output: Contribution to journalArticle

Palomba, S, Manguso, F, Orio, F, Russo, T, Oppedisano, R, Sacchinelli, A, Falbo, A, Tolino, A, Zullo, F & Mastrantonio, P 2008, 'Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: A prospective, parallel, open-label, two-year extension study', Menopause, vol. 15, no. 4, pp. 730-736. https://doi.org/10.1097/gme.0b013e318159f190
Palomba, Stefano ; Manguso, Francesco ; Orio, Francesco ; Russo, Tiziana ; Oppedisano, Rosamaria ; Sacchinelli, Angela ; Falbo, Angela ; Tolino, Achille ; Zullo, Fulvio ; Mastrantonio, Pasquale. / Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease : A prospective, parallel, open-label, two-year extension study. In: Menopause. 2008 ; Vol. 15, No. 4. pp. 730-736.
@article{c4ef6bbec63840e0bd6fbdbee5fb4098,
title = "Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: A prospective, parallel, open-label, two-year extension study",
abstract = "Objective: To evaluate long-term efficacy of risedronate in osteoporotic postmenopausal patients with inflammatory bowel disease (IBD). Design: A prospective, parallel, open-label, 2-year extension study of a randomized, double-blind, 1-year clinical trial. Eighty-one osteoporotic postmenopausal women with IBD were treated with risedronate (n = 40) or placebo (n = 41). Bone mineral density (BMD), biochemical bone turnover markers, and vertebral and nonvertebral fractures were assessed throughout the study. Data were analyzed using the intent-to-treat principle. Results: Significant (P",
keywords = "Bone fractures, Inflammatory bowel disease, Osteoporosis, Postmenopause, Risedronate",
author = "Stefano Palomba and Francesco Manguso and Francesco Orio and Tiziana Russo and Rosamaria Oppedisano and Angela Sacchinelli and Angela Falbo and Achille Tolino and Fulvio Zullo and Pasquale Mastrantonio",
year = "2008",
month = "7",
doi = "10.1097/gme.0b013e318159f190",
language = "English",
volume = "15",
pages = "730--736",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease

T2 - A prospective, parallel, open-label, two-year extension study

AU - Palomba, Stefano

AU - Manguso, Francesco

AU - Orio, Francesco

AU - Russo, Tiziana

AU - Oppedisano, Rosamaria

AU - Sacchinelli, Angela

AU - Falbo, Angela

AU - Tolino, Achille

AU - Zullo, Fulvio

AU - Mastrantonio, Pasquale

PY - 2008/7

Y1 - 2008/7

N2 - Objective: To evaluate long-term efficacy of risedronate in osteoporotic postmenopausal patients with inflammatory bowel disease (IBD). Design: A prospective, parallel, open-label, 2-year extension study of a randomized, double-blind, 1-year clinical trial. Eighty-one osteoporotic postmenopausal women with IBD were treated with risedronate (n = 40) or placebo (n = 41). Bone mineral density (BMD), biochemical bone turnover markers, and vertebral and nonvertebral fractures were assessed throughout the study. Data were analyzed using the intent-to-treat principle. Results: Significant (P

AB - Objective: To evaluate long-term efficacy of risedronate in osteoporotic postmenopausal patients with inflammatory bowel disease (IBD). Design: A prospective, parallel, open-label, 2-year extension study of a randomized, double-blind, 1-year clinical trial. Eighty-one osteoporotic postmenopausal women with IBD were treated with risedronate (n = 40) or placebo (n = 41). Bone mineral density (BMD), biochemical bone turnover markers, and vertebral and nonvertebral fractures were assessed throughout the study. Data were analyzed using the intent-to-treat principle. Results: Significant (P

KW - Bone fractures

KW - Inflammatory bowel disease

KW - Osteoporosis

KW - Postmenopause

KW - Risedronate

UR - http://www.scopus.com/inward/record.url?scp=51449103370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51449103370&partnerID=8YFLogxK

U2 - 10.1097/gme.0b013e318159f190

DO - 10.1097/gme.0b013e318159f190

M3 - Article

C2 - 18698280

AN - SCOPUS:51449103370

VL - 15

SP - 730

EP - 736

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 4

ER -